Hallucinogenic drug interactions at human brain 5-HT2 receptors: implications for treating LSD-induced hallucinogenesis
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
It has been shown that the hallucinogenic potencies of LSD, the phenylisopropylamines, such as DOB (4-bromo-2,5-dimethoxyphenylisopropylamine) and DOI (4-iodo-2,5-dimethoxyphenylisopropylamine), and the indolealkylamines, such as DMT (dimethyltryptamine) and 5-OMe-DMT (5-methoxy-dimethyltryptamine), strongly correlate with their in vitro 5-HT2 receptor binding affinities in rat cortical homogenates. In order to ascertain if this correlation applies to human 5-HT2 receptors as well, we examined the affinities of 13 psychoactive compounds at 3H-ketanserin-labelled 5-HT2 receptors in human cortical samples. Both radioligand binding and autoradiographical procedures were used. As in rat brain, d-LSD was the most potent displacer of 3H-ketanserin specific binding with a Ki of 0.9 nM. The phenylisopropylamine DOI also displayed high affinity (Ki of 6 nM). Stereospecific interactions were found with DOB; (-) DOB had a Ki of 17 nM while (+) DOB had a Ki of 55 nM. The behaviorally active compound DOM (4-methyl-2,5-phenylisopropylamine) had an affinity of 162 nM while its behaviorally less active congener iso-DOM had an affinity of 6299 nM. The indolealkylamines 5-OMe-DMT and DMT competed with moderate affinities (207 and 462 nM, respectively). In general, Hill coefficients were significantly less than unity which is consistent with an agonist interaction with 5-HT2 receptors. MDMA, a substituted amphetamine analog was inactive with a Ki of greater than 10 microM. A strong correlation…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The prototypic tryptamine hallucinogen DMT (9) had a Ki of 0.5 µM [47] or 2 µM [48] against (mainly) 5HT2A/C sites labelled with [3H]-ketanserin, indicating rather low affinity in vitro.”
From Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans. (2021) · cites this paper as [47]
In the citing paper
“Indeed, the strong association between hallucinogenic properties of a broad range of structural classes of molecules with 5HT2A affinity supports the use of antagonist drugs like ketanserin (7) as a treatment for drug-induced hallucinations [47].”
From Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans. (2021) · cites this paper as [47]
In the citing paper
“5-MeO-DMT (15) has similar affinity at 5HT2A receptors (Ki = 200 nM), under binding conditions where LSD (1) had a Ki of only 1 nM [47], and had >100-fold selectivity for 5HT1A/B/C receptors relative to 5HT2A receptors in vitro [56].”
From Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans. (2021) · cites this paper as [47]
Citations
Cites
Handbook of Psychopharmacology
(1978) · Springer eBooks · doi:10.1007/978-1-4613-4042-3 · Cited by 1,091
A practical computer-based approach to the analysis of radioligand binding experiments
McPherson, G. A. (1983) · Computer Programs in Biomedicine · doi:10.1016/0010-468x(83)90031-4 · Cited by 829
Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents
Glennon, R. A., Titeler, M., & McKenney, J. D. (1984) · Life Sciences · doi:10.1016/0024-3205(84)90436-3 · Cited by 631
Self-citationTiteler, M., Lyon, R. A., & Glennon, R. A. (1988) · Psychopharmacology · doi:10.1007/bf00176847 · Cited by 343 · cited 4×
“It has been recently shown that certain phenylisopropylamines such as DOB (Titeler et al. 1988) and DOI (Hoyer and Karpf 1988) have high affinity for the 5-HT1C receptor and that a significant correlation exists between hallucinogenic potency and 5-HT1C receptor binding affinity ( Titeler et al. 1988 ).”
BackgroundResultInfluentialSelf-citationGlennon, R. A., Young, R., & Rosecrans, J. A. (1983) · European Journal of Pharmacology · doi:10.1016/0014-2999(83)90464-8 · Cited by 190
Self-citationPsychotomimetic Drugs: Structure-Activity Relationships
Shulgin, A. T. (1978) · Springer eBooks · doi:10.1007/978-1-4757-0510-2_6 · Cited by 131
Shannon, M. H., Battaglia, G., Glennon, R. A., & Titeler, M. (1984) · European Journal of Pharmacology · doi:10.1016/0014-2999(84)90333-9 · Cited by 128
Self-citationLyon, R. A., Glennon, R., & Titeler, M. (1986) · Psychopharmacology · doi:10.1007/bf00178519 · Cited by 121
Self-citationLyon, R. A., Davis, K. H., & Titeler, M. (1987) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)10354-4 · Cited by 106
Self-citationRasmussen, K., & Aghajanian, G. K. (1986) · Brain Research · doi:10.1016/0006-8993(86)91090-5 · Cited by 103
Glennon, R. A., Seggel, M. R., Soine, W. H., Herrick-Davis, K., Lyon, R. A., & Titeler, M. (1988) · Journal of Medicinal Chemistry · doi:10.1021/jm00396a003 · Cited by 100
Self-citationGlennon, R. A., Rosecrans, J. A., & Young, R. (1983) · Medicinal Research Reviews · doi:10.1002/med.2610030305 · Cited by 89
Self-citation[3H]DOB: A specific agonist radioligand for 5-HT2 serotonin receptors
Titeler, M., Herrick, K. F., Lyon, R. A., MCKENNEY, J. D. J., & Glennon, R. A. (1985) · European Journal of Pharmacology · doi:10.1016/0014-2999(85)90486-8 · Cited by 68
Self-citationDiscriminative stimulus properties of MDA analogs.
Glennon, R. A., Young, R., Rosecrans, J. A., & Gm, A. (1982) · PubMed · Cited by 64
Self-citationIndolealkylamine analogs share 5-HT2 binding characteristics with phenylalkylamine hallucinogens
Lyon, R. A., Titeler, M., Seggel, M. R., & Glennon, R. A. (1988) · European Journal of Pharmacology · doi:10.1016/0014-2999(88)90432-3 · Cited by 54
Self-citationHoyer, D., & Karpf, A. (1988) · European Journal of Pharmacology · doi:10.1016/0014-2999(88)90766-2 · Cited by 43
Leysen, J. E., Eens, A., Gommeren, W., Gompel, P. V., Wynants, J., & Janssen, P. A. J. (1987) · European Journal of Pharmacology · doi:10.1016/0014-2999(87)90373-6 · Cited by 34
2-Pyrrolidinone and succinimide endogenously present in several mammalian species
Bandle, E. F., Wendt, G., Ranalder, U. B., & Trautmann, K. H. (1984) · Life Sciences · doi:10.1016/0024-3205(84)90461-2 · Cited by 27
Battaglia, G., Shannon, M. H., Borgundvaag, B., & Titeler, M. (1983) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1983.tb04772.x · Cited by 20
Self-citation
Cited by
The Pharmacology and Clinical Pharmacology of 3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”)
Green, A. R., Mechan, A. O., Elliott, J. M., O’Shea, E., & Colado, M. I. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.3.3 · Cited by 1,272
Nichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211
Nichols, D. E., & Nichols, C. D. (2008) · Chemical Reviews · doi:10.1021/cr078224o · Cited by 895
Vollenweider, F. (1997) · Neuropsychopharmacology · doi:10.1016/s0893-133x(96)00246-1 · Cited by 444
Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens
Halberstadt, A. L., & Geyer, M. A. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.01.017 · Cited by 411
Metadata
- Authors
- Sadzot, B., Baraban, J. M., Glennon, R. A., Lyon, R. A., Leonhardt, S., Jan, C.-R., & Titeler, M.
- Affiliations
- Johns Hopkins University (US)
- Virginia Commonwealth University (US)
- Procter & Gamble (United States) (US)
- Albany Medical College (US)
- Venue
- Psychopharmacology
- Published
- 1989-08
- Volume
- 98
- Issue
- 4
- Pages
- 495-499
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- OpenAlex
- W2028308920
- Cited by
- 132
- References
- 19
- Citations by year
- 2026: 5 · 2025: 1 · 2024: 3 · 2023: 2 · 2022: 5 · 2021: 3 · 2020: 5 · 2019: 4 · 2018: 4 · 2017: 4 · 2016: 4 · 2015: 4 · 2014: 4 · 2013: 1 · 2012: 3
- FWCI
- 5.25
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Mental Health (MH40716)
- National Institute on Drug Abuse (DA00026)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cognitive Neuroscience › Hallucinations in medical conditions
- Keywords
- LSD, 5-HT2 receptor, serotonin receptors, ketanserin binding, DOB, digital object identifiers, DOM, DMT, stereospecific binding, MDMA, receptor binding affinity, 5-HT2 receptor antagonist, phenylisopropylamines, indolealkylamines, Hill coefficient
- MeSH terms
- Animals, Binding, Competitive, Cerebral Cortex, Hallucinations, Hallucinogens, Humans, Ketanserin, Lysergic Acid Diethylamide, Receptors, Serotonin, Rats, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.